INTERPHEX 2019 Keynote Series: Contamination in Aseptic Manufacturing
In a keynote session at INTERPHEX 2019, experts will review and debate the issues and present potential solutions for contamination issues in aseptic manufacturing.
Ongoing product recalls, warning letters, and questions about the revisions to the European Union’s GMP Annex 1, present challenges and opportunities in aseptic drug manufacturing. In a keynote session at INTERPHEX 2019, experts will review and debate the issues, and present potential solutions.
Wednesday, April 3: 1:30–3 pm
Minimizing Contamination in Aseptic Manufacturing
Experts look at new technologies, approaches, and services that are preventing contamination, recalls, and regulatory noncompliance in a crucial area of drug manufacturing.
Moderator: Agnes Shanley, senior editor, Pharmaceutical Technology
1:30–2 pm
Aseptic Processing: Industry Trends and Challenges
Jim Agalloco, principal, Agalloco Associates
2:15–2:40 pm
Tech Talk: Top Issues and How New Technologies and Services Address Them
Learn about current industry challenges related to aseptic processing and possible solutions including new technology advances, supply chain integration, and enhanced roles for CDMOs.
Panelists:
Chris Procyshyn, CEO, VanRx
Jo Anne Jacobs, fellow and manufacturing technology specialist, Catalent
Nicholas Zasada, director of process development and manufacturing, Vetter Development Services USA, Inc.
Paul Lopolito, technical service senior manager, Steris Corporation, Life Science Formulated Chemistries
Arnab Ganguly, scientist and technology manager, IMA Life North America, Inc.
Moderator: Jim Agalloco, principal, Agalloco Associates
2:40–3:15 pm
Regulatory Issues and Innovationâ¯
Experts will debate key issues related to aseptic processing and regulatory oversight including the following:
- Ending the Catch 22 of aseptic technology innovation: How can regulators encourage the use of innovative technologies when they haven’t yet been mentioned in a new drug application or other filing?
- Annexâ¯I: Does it signal deeper misunderstandings of basic concepts and science on the part of regulators, and what can be done about it?
Panelists:
Jim Agalloco, principal, Agalloco Associates
Chris Procyshyn, CEO, VanRx
Jo Anne Jacobs, fellow and manufacturing technology specialist, Catalent
Nicholas Zasada, director of process development and manufacturing, Vetter Development Services USA, Inc.
Click here to see more Keynote series information.
Click here and use promo code IPXREG to register for INTERPHEX.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
